Would the cost-cutting measures for U.S. prescription drugs proposed by the Trump administration on Monday hurt the biotech ...

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

A BioSpace survey found that 56% of employed and 81% of unemployed respondents are considering jobs outside biopharma. Some ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on ...

We hoped industry layoffs would relent in ... Story Feb. 6 - X4 Pharmaceuticals: The rare disease biotech is laying off 43 employees—equivalent to 30% of the company’s total staffers—along ...

In an era of rapid digital transformation, the pharmaceutical industry is increasingly leveraging advanced integration technologies to streamline operations and enhance efficiency. Rishi Nareshbhai ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Distribution Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering.

On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry ... Many of the pharmaceutical company ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's ...